BRIEF-Alexion receives positive CHMP opinion for Soliris in the EU
* Alexion receives positive CHMP opinion for Soliris (eculizumab) for the treatment of patients with refractory Generalized Myasthenia Gravis (GMG) in the European Union
SHANGHAI, June 16 Shanghai Disneyland's first year was encouraging and the "right precursors" are in place for development of the brand in China, Bob Chapek, head of parks and resorts at Walt Disney Co, told reporters on Friday.
"We're extraordinarily encouraged by the unbelievable result of 11 million guests in the first year and more important than that, the satisfaction scores that we get are extraordinarily high. And I think those are the sort of right precursors, if you will, for future development," he said when asked about expansion plans.
"We're very encouraged by what we've seen." (Reporting by Brenda Goh; Writing by John Ruwitch; Editing by Clarence Fernandez)
* Ultragenyx pharmaceutical inc - based on agreement, submission of burosumab bla is planned for second half of 2017
* Perficient Inc - acquisition is expected to be accretive to adjusted earnings per share immediately